PURPOSE: This retrospective study was carried out to evaluate the efficacy and toxicity of radiation therapy (RT) with/without cisplatin-based chemotherapy in nasopharyngeal cancer (NPC). MATERIALS AND METHODS: One hundred forty six patients with NPC received curative RT and/or cisplatin-based chemotherapy. Thirty-nine patients were treated with induction chemotherapy (IC), including cisplatin and 5-fluorouracil followed by RT. Another 63 patients were treated with concurrent chemoradiotherapy (CCRT) using cisplatin, and 22 patients were treated with IC followed by CCRT. The remaining 22 patients were treated with RT alone. RESULTS: One hundred four (80.0%) patients achieved complete response (CR), and 23 (17.7%) patients achieved partial response (PR). The patterns of failure were: locoregional recurrences in 21.2% and distant metastases in 17.1%. Five-year overall survival (OS) and progression free survival (PFS) were 50.7% and 45.0%, respectively. Multivariate Cox stepwise regression analysis revealed CR to chemoradiotherapy to be a powerful prognostic factor for OS. CR to chemoradiotherapy and completion of radiation according to the time schedule were favorable prognostic factors for PFS. A comparison of each treatment group (IC --> RT vs. CCRT vs. IC --> CCRT vs. RT alone) revealed no significant differences in the OS or PFS. However, subgroup analysis showed significant differences in both OS and DFS in favor of the combined chemoradiotherapy group compared with RT alone, for stage IV and T3-4 tumors. Grade 3-4 toxicities were more common in the combined chemoradiotherapy arm, particularly in the CCRT group. CONCLUSIONS: This study was limited in that it was a retrospective study, much time was required to collect patients, and there were imbalances in the number of patients in each treatment group. Combined chemoradiotherapy remarkably prolonged the OS and PFS in subgroup patients with stage IV or T3-4 NPC.
PURPOSE: This retrospective study was carried out to evaluate the efficacy and toxicity of radiation therapy (RT) with/without cisplatin-based chemotherapy in nasopharyngeal cancer (NPC). MATERIALS AND METHODS: One hundred forty six patients with NPC received curative RT and/or cisplatin-based chemotherapy. Thirty-nine patients were treated with induction chemotherapy (IC), including cisplatin and 5-fluorouracil followed by RT. Another 63 patients were treated with concurrent chemoradiotherapy (CCRT) using cisplatin, and 22 patients were treated with IC followed by CCRT. The remaining 22 patients were treated with RT alone. RESULTS: One hundred four (80.0%) patients achieved complete response (CR), and 23 (17.7%) patients achieved partial response (PR). The patterns of failure were: locoregional recurrences in 21.2% and distant metastases in 17.1%. Five-year overall survival (OS) and progression free survival (PFS) were 50.7% and 45.0%, respectively. Multivariate Cox stepwise regression analysis revealed CR to chemoradiotherapy to be a powerful prognostic factor for OS. CR to chemoradiotherapy and completion of radiation according to the time schedule were favorable prognostic factors for PFS. A comparison of each treatment group (IC --> RT vs. CCRT vs. IC --> CCRT vs. RT alone) revealed no significant differences in the OS or PFS. However, subgroup analysis showed significant differences in both OS and DFS in favor of the combined chemoradiotherapy group compared with RT alone, for stage IV and T3-4 tumors. Grade 3-4 toxicities were more common in the combined chemoradiotherapy arm, particularly in the CCRT group. CONCLUSIONS: This study was limited in that it was a retrospective study, much time was required to collect patients, and there were imbalances in the number of patients in each treatment group. Combined chemoradiotherapy remarkably prolonged the OS and PFS in subgroup patients with stage IV or T3-4 NPC.
Authors: D T Chua; J S Sham; D Choy; V Lorvidhaya; Y Sumitsawan; S Thongprasert; V Vootiprux; A Cheirsilpa; T Azhar; A H Reksodiputro Journal: Cancer Date: 1998-12-01 Impact factor: 6.860
Authors: A W Lee; Y F Poon; W Foo; S C Law; F K Cheung; D K Chan; S Y Tung; M Thaw; J H Ho Journal: Int J Radiat Oncol Biol Phys Date: 1992 Impact factor: 7.038
Authors: P Teo; P Yu; W Y Lee; S F Leung; W H Kwan; K H Yu; P Choi; P J Johnson Journal: Int J Radiat Oncol Biol Phys Date: 1996-09-01 Impact factor: 7.038
Authors: Anne W M Lee; W H Lau; Stewart Y Tung; Daniel T T Chua; Rick Chappell; L Xu; Lillian Siu; W M Sze; T W Leung; Jonathan S T Sham; Roger K C Ngan; Stephen C K Law; T K Yau; Joseph S K Au; Brian O'Sullivan; Ellie S Y Pang; S K O; Gordon K H Au; Joseph T Lau Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: A T C Chan; P M L Teo; R K Ngan; T W Leung; W H Lau; B Zee; S F Leung; F Y Cheung; W Yeo; H H Yiu; K H Yu; K W Chiu; D T Chan; T Mok; K T Yuen; F Mo; M Lai; W H Kwan; P Choi; P J Johnson Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: E H Tan; E T Chua; J Wee; T Tan; K W Fong; P T Ang; K S Lee; K M Lee; H S Khoo-Tan; S S Leong; Y K Ong; K F Foo; V K Sethi; E J Chua Journal: Int J Radiat Oncol Biol Phys Date: 1999-10-01 Impact factor: 7.038
Authors: A T Chan; P M Teo; T W Leung; S F Leung; W Y Lee; W Yeo; P H Choi; P J Johnson Journal: Int J Radiat Oncol Biol Phys Date: 1995-10-15 Impact factor: 7.038
Authors: Baoai Han; Xiuping Yang; Po Zhang; Ya Zhang; Yaqin Tu; Zuhong He; Yongqin Li; Jie Yuan; Yaodong Dong; Davood K Hosseini; Tao Zhou; Haiying Sun Journal: PLoS One Date: 2020-04-09 Impact factor: 3.240